Keywords: ph, iii, data, amgen/praecis, cancer, drug, amgen
Ph III data with Amgen/Praecis' cancer drug
Article | 25 May 2000
Amgen and Praecis Pharmaceuticals presented positive pivotal data fromtrials of their jointly-developed prostate cancer drug, abarelix-depot-M, at the recent American ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
